Faron Pharmaceuticals Ltd | Press Release | June 30, 2025 at 09:00:00 EEST Study details how bexmarilimab treatment reduces circulating sClever-1 in patients with cancer, a key factor in T-cell suppression and PD-1 therapy resistance TURKU, FINLAND –...
Est. reading time: 5 minutes